Janux Therapeutics

Share price falling

Biotech

Analyst deems Janux's stock spiral an 'overreaction'

Since the market closed Monday, Janux’s stock has plummeted 48%, falling from $33.99 per share to $17.7 as of 11 a.m. ET today.

Gabrielle Masson Dec 2, 2025 11:14am

skydiving mountain parachute

Takeda taps Julie Kim as new CEO—Chutes & Ladders

Jan 31, 2025 8:30am

cancer cell lymphocytes T cells cancer

Janux's T-cell engager makes waves, again, with new data drop

Dec 3, 2024 11:40am

An artists concept of T cells attacking a cancer cell The T cells are in red while the cancer is light blue The cells are

Janux's shares jump 130% following T-cell engager data drop

Feb 27, 2024 10:35am

signing contract

Merck-partnered Janux hires CMO as its bispecifics near clinic

Jun 4, 2021 8:05am

Janux CEO David Campbell

Janux seeks $100M IPO on preclinical promise of bispecifics

May 21, 2021 6:55am